Sentiment-Signal
6,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Unternehmen & Branche
| Name | Olema Pharmaceuticals, Inc. |
|---|---|
| Ticker | OLMA |
| CIK | 0001750284 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,29 Mrd. USD |
| Beta | 2,18 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -162,451,000 | -1.87 | 533,430,000 | 478,559,000 | |
| 2025-09-30 | 10-Q | -42,217,000 | -0.49 | 352,453,000 | 307,488,000 | |
| 2025-06-30 | 10-Q | -43,784,000 | -0.51 | 382,002,000 | 345,236,000 | |
| 2025-03-31 | 10-Q | -30,389,000 | -0.36 | 409,639,000 | 383,452,000 | |
| 2024-12-31 | 10-K | -129,474,000 | -2.20 | 450,979,000 | 408,964,000 | |
| 2024-09-30 | 10-Q | -34,555,000 | -0.60 | 230,173,000 | 198,911,000 | |
| 2024-06-30 | 10-Q | -30,382,000 | -0.54 | 254,557,000 | 227,163,000 | |
| 2024-03-31 | 10-Q | -30,970,000 | -0.56 | 263,694,000 | 236,318,000 | |
| 2023-12-31 | 10-K | -96,655,000 | -2.14 | 276,945,000 | 253,895,000 | |
| 2023-09-30 | 10-Q | -21,502,000 | -0.48 | 292,799,000 | 275,134,000 | |
| 2023-06-30 | 10-Q | -20,095,000 | -0.49 | 177,624,000 | 161,583,000 | |
| 2023-03-31 | 10-Q | -28,286,000 | -0.70 | 195,768,000 | 174,975,000 | |
| 2022-12-31 | 10-K | -104,787,000 | -2.62 | 215,645,000 | 197,546,000 | |
| 2022-09-30 | 10-Q | -22,720,000 | -0.57 | 231,997,000 | 217,699,000 | |
| 2022-06-30 | 10-Q | -32,858,000 | -0.82 | 250,600,000 | 236,283,000 | |
| 2022-03-31 | 10-Q | -23,030,000 | -0.58 | 277,418,000 | 265,090,000 | |
| 2021-12-31 | 10-K | -71,096,000 | -1.80 | 295,945,000 | 284,568,000 | |
| 2021-09-30 | 10-Q | -17,713,000 | -0.45 | 309,795,000 | 300,894,000 | |
| 2021-06-30 | 10-Q | -16,406,000 | -0.42 | 322,230,000 | 314,084,000 | |
| 2021-03-31 | 10-Q | -15,339,000 | -0.39 | 331,301,000 | 326,024,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Mitchell Shawnte | Officer, CHIEF LEGAL OFFICER | Open Market Sale | -233 | 24.69 | -5,752.77 | -0,6% | |
| 2026-03-04 | Mitchell Shawnte | Officer, CHIEF LEGAL OFFICER | Open Market Sale | -24,767 | 24.25 | -600,599.75 | -65,8% | |
| 2026-03-03 | Mitchell Shawnte | Officer, CHIEF LEGAL OFFICER | Open Market Sale | -15,000 | 23.01 | -345,150.00 | -37,8% | |
| 2026-01-20 | Harmon Cyrus | Director | Open Market Sale | -10,000 | 26.88 | -268,800.00 | -29,4% | |
| 2026-01-15 | Kovacs Shane William Charles | Officer, CH. OPERATING & FINANCIAL OFF. | Open Market Sale | -100,000 | 28.73 | -2,873,000.00 | -314,7% | |
| 2026-01-14 | Harmon Cyrus | Director | Open Market Sale | -3,489 | 29.12 | -101,599.68 | -11,1% | |
| 2026-01-14 | Myles David C. | Officer, CH. DISCOV. & NON-CLIN DEV OFF | Open Market Sale | -14,997 | 28.60 | -428,914.20 | -47,0% | |
| 2026-01-14 | Myles David C. | Officer, CH. DISCOV. & NON-CLIN DEV OFF | Open Market Sale | -35,003 | 28.99 | -1,014,736.97 | -111,1% | |
| 2026-01-13 | Myles David C. | Officer, CH. DISCOV. & NON-CLIN DEV OFF | Open Market Sale | -49,800 | 27.60 | -1,374,480.00 | -150,5% | |
| 2026-01-13 | Kovacs Shane William Charles | Officer, CH. OPERATING & FINANCIAL OFF. | Open Market Sale | -3,822 | 28.01 | -107,054.22 | -11,7% | |
| 2026-01-13 | Myles David C. | Officer, CH. DISCOV. & NON-CLIN DEV OFF | Open Market Sale | -200 | 28.49 | -5,698.00 | -0,6% | |
| 2026-01-12 | Myles David C. | Officer, CH. DISCOV. & NON-CLIN DEV OFF | Open Market Sale | -10,000 | 28.34 | -283,400.00 | -31,0% | |
| 2025-12-23 | Zojwalla Naseem | Officer, Chief Medical Officer | Open Market Sale | -99,509 | 27.66 | -2,752,418.94 | -301,4% | |
| 2025-12-22 | Zojwalla Naseem | Officer, Chief Medical Officer | Open Market Sale | -100,000 | 28.04 | -2,804,000.00 | -307,1% | |
| 2025-12-22 | Harmon Cyrus | Director | Open Market Sale | -2,881 | 28.53 | -82,194.93 | -9,0% | |
| 2025-12-19 | CLARK IAN T | Director | Open Market Sale | -193,056 | 29.71 | -5,735,693.76 | -628,2% | |
| 2025-12-19 | Myles David C. | Officer, CH. DISCOV. & NON-CLIN DEV OFF | Open Market Sale | -1,225 | 28.08 | -34,398.00 | -3,8% | |
| 2025-12-19 | Myles David C. | Officer, CH. DISCOV. & NON-CLIN DEV OFF | Open Market Sale | -6,046 | 31.39 | -189,783.94 | -20,8% | |
| 2025-12-19 | Myles David C. | Officer, CH. DISCOV. & NON-CLIN DEV OFF | Open Market Sale | -43,729 | 30.40 | -1,329,361.60 | -145,6% | |
| 2025-12-19 | Zojwalla Naseem | Officer, Chief Medical Officer | Open Market Sale | -12,921 | 28.93 | -373,804.53 | -40,9% | |
| 2025-12-19 | Zojwalla Naseem | Officer, Chief Medical Officer | Open Market Sale | -57,079 | 28.03 | -1,599,924.37 | -175,2% | |
| 2025-12-19 | CLARK IAN T | Director | Open Market Sale | -29,904 | 28.83 | -862,132.32 | -94,4% | |
| 2025-12-19 | CLARK IAN T | Director | Open Market Sale | -41,840 | 30.48 | -1,275,283.20 | -139,7% | |
| 2025-09-18 | Harmon Cyrus | Director | Open Market Sale | -10,000 | 8.33 | -83,300.00 | -9,1% | |
| 2025-09-18 | Harmon Cyrus | Director | Open Market Sale | -3,086 | 8.32 | -25,675.52 | -2,8% | |
| 2025-09-16 | Harmon Cyrus | Director | Open Market Sale | -1,914 | 8.08 | -15,465.12 | -1,7% | |
| 2025-09-16 | Harmon Cyrus | Director | Open Market Sale | -10,000 | 8.04 | -80,400.00 | -8,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.